Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Dendreon (NASDAQ: DNDN) price target raiesd from $16 to $18.
Analyst, George Farmer, said, "We maintain our rating and raise our target as a negative FDA stance on Amgen’s (Nasdaq: AMGN) XGEVA de-risks the outlook for DNDN’s prostate cancer vaccine, Provenge."
"Encouraging December sales in the face of holiday conflicts had justified our previously bumped-up 2012 $426M sales estimate. Our new 2012 $458M estimate assumes near-term acceleration of “same-store-sales” fueled by higher physician perception, although we caution that negative practitioner impressions of logistics and cost still lingers. Nevertheless, $500M in sales this year – a management-declared cash flow break-even point – is not far fetched, in our view."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $16.53 yesterday.
Analyst, George Farmer, said, "We maintain our rating and raise our target as a negative FDA stance on Amgen’s (Nasdaq: AMGN) XGEVA de-risks the outlook for DNDN’s prostate cancer vaccine, Provenge."
"Encouraging December sales in the face of holiday conflicts had justified our previously bumped-up 2012 $426M sales estimate. Our new 2012 $458M estimate assumes near-term acceleration of “same-store-sales” fueled by higher physician perception, although we caution that negative practitioner impressions of logistics and cost still lingers. Nevertheless, $500M in sales this year – a management-declared cash flow break-even point – is not far fetched, in our view."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $16.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
